Press Releases

Date Title and Summary Additional Formats
Toggle Summary Sam’s Club and Dynavax Technologies Corporation Announce Collaboration to Make HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Available to Sam’s Club Patients
BERKELEY, Calif. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a leader in developing immunotherapies based on toll-like receptor (TLR) biology, and Sam’s Club, a leading membership warehouse club offering superior products, savings and services to millions of
View HTML
Toggle Summary Dynavax to Present at 37th Annual J.P. Morgan Healthcare Conference
BERKELEY, Calif. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced that Eddie Gray , Chief Executive Officer, will
View HTML
Toggle Summary Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B Launch, and Updated SD-101 Data in Three Patient Populations
Conference Call to be held Today at 4:30pm ET / 1:30pm PT BERKELEY, Calif. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2018 along with an update on the launch progress of HEPLISAV-B
View HTML
Toggle Summary Dynavax to Host Third Quarter 2018 Financial Results Conference Call
BERKELEY, Calif. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will report financial results for the third quarter ended September 30, 2018 after market close on Monday, November 5, 2018 , and host a conference call that day to review
View HTML
Toggle Summary Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 2018 Congress
- 70% overall response rate (33/47 patients) at 2 mg dose of SD-101 includes 17 additional patients - -Progression free survival, response rate in patients with PDL-1 negative tumors and biomarker activity supports clinical impact of SD-101’s activity- - Conference call and webcast to review all
View HTML
Toggle Summary Dynavax Technologies and Quantum Leap Healthcare Collaborative Announce Selection of SD-101 Combined with KEYTRUDA® (pembrolizumab) in the I-SPY 2 TRIAL For Breast Cancer
BERKELEY, Calif. and SAN FRANCISCO , Oct. 15, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) and Quantum Leap Healthcare Collaborative™ (QLHC) announced today that the immunotherapy combination of Dynavax’s proprietary investigational compound SD-101 and KEYTRUDA®
View HTML
Toggle Summary Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the European Society for Medical Oncology 2018 Congress
BERKELEY, Calif. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that data will be presented from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA ® (pembrolizumab), an anti-PD-1
View HTML
Toggle Summary Dynavax to Present at the 2018 Cantor Global Healthcare Conference
BERKELEY, Calif. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that Eddie Gray , Dynavax’s Chief Executive Officer, will present at the 2018 Cantor Global Healthcare Conference on Monday, October 1, 2018 at 10:40 AM ET at the InterContinental
View HTML
Toggle Summary Dynavax Announces Publication of Preclinical Study of TLR9 Agonist in Lung Cancer
Delivery of a TLR9 Agonist Through the Airways Complements PD-1 Blockade to Generate Durable, Systemic Anti-tumor Immunity BERKELEY, Calif. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced publication of a preclinical study demonstrating that
View HTML
Toggle Summary Dynavax Announces Publication of Two Papers in Leading Oncology Journal Highlighting Data From Clinical Studies of Its TLR9 Agonist, SD-101
Cancer Discovery Features Reports of Early Clinical Trials of SD-101 in Lymphoma and Advanced Melanoma BERKELEY, Calif. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that two peer-reviewed papers reporting clinical studies of SD-101 have been
View HTML